Characterization of transferrin receptor-mediated endocytosis and cellular iron delivery of recombinant human serum transferrin from rice (Oryza sativaL.)
© Zhang et al.; licensee BioMed Central Ltd. 2012
Received: 15 August 2012
Accepted: 23 November 2012
Published: 30 November 2012
Transferrin (TF) plays a critical physiological role in cellular iron delivery via the transferrin receptor (TFR)-mediated endocytosis pathway in nearly all eukaryotic organisms. Human serum TF (hTF) is extensively used as an iron-delivery vehicle in various mammalian cell cultures for production of therapeutic proteins, and is also being explored for use as a drug carrier to treat a number of diseases by employing its unique TFR-mediated endocytosis pathway. With the increasing concerns over the risk of transmission of infectious pathogenic agents of human plasma-derived TF, recombinant hTF is preferred to use for these applications. Here, we carry out comparative studies of the TFR binding, TFR-mediated endocytosis and cellular iron delivery of recombinant hTF from rice (rhTF), and evaluate its suitability for biopharmaceutical applications.
Through a TFR competition binding affinity assay with HeLa human cervic carcinoma cells (CCL-2) and Caco-2 human colon carcinoma cells (HTB-37), we show that rhTF competes similarly as hTF to bind TFR, and both the TFR binding capacity and dissociation constant of rhTF are comparable to that of hTF. The endocytosis assay confirms that rhTF behaves similarly as hTF in the slow accumulation in enterocyte-like Caco-2 cells and the rapid recycling pathway in HeLa cells. The pulse-chase assay of rhTF in Caco-2 and HeLa cells further illustrates that rice-derived rhTF possesses the similar endocytosis and intracellular processing compared to hTF. The cell culture assays show that rhTF is functionally similar to hTF in the delivery of iron to two diverse mammalian cell lines, HL-60 human promyelocytic leukemia cells (CCL-240) and murine hybridoma cells derived from a Sp2/0-Ag14 myeloma fusion partner (HB-72), for supporting their proliferation, differentiation, and physiological function of antibody production.
The functional similarity between rice derived rhTF and native hTF in their cellular iron delivery, TFR binding, and TFR-mediated endocytosis and intracellular processing support that rice-derived rhTF can be used as a safe and animal-free alternative to serum hTF for bioprocessing and biopharmaceutical applications.
KeywordsRecombinant human serum transferrin Transferrin receptor Endocytosis Cell growth and proliferation Antibody production
Iron is an essential element for cell growth and metabolism. The major vehicle for iron delivery is serum transferrin (TF), which plays a crucial role in tightly regulating cellular iron uptake, transport, and utilization in nearly all eukaryotes. The mechanism by which TF overcomes the dual challenges of iron deficiency and overload in cells is via a TF/TF receptor (TFR)-mediated endocytotic process . When TF is free of iron (apo-TF), it can bind two iron molecules (diferric TF or holo-TF) at the extracellular pH of 7.4. The resultant holo-TF binds to TFR with a greater affinity than apo-TF, where two diferric TF molecules will bind to the homodimeric TFR on the cell surface . This TF–TFR complex is then endocytosed into the early endosome, where the acidic environment (pH 5.5) triggers the conformational change of TF–TFR complex and the subsequent release of iron from TF. Finally, the TF–TFR complex is recycled to the cell surface, where the lower affinity of apo-TF for TFR at the neutral extracellular pH will dissociate the complex and release the TF for re-use .
TF has been successfully used or being evaluated in a wide range of important biopharmaceutical applications. TF has been widely used as an important supplement in culture medium for various mammalian cells and stem cells because of the absolute requirement of iron for cellular growth and proliferation [4, 5]. TF has also been actively pursued as a drug delivery vehicle due to its unique receptor-mediated endocytosis pathway as well as its added advantages of being biodegradable, nontoxic, and nonimmunogenic [6–9]. Moreover, TF is also exploited for oral delivery of protein-based therapeutics [10, 11], as TFR is abundantly expressed in human gastrointestinal (GI) epithelium and TF is resistant to proteolytic degradation [10, 12].
With the increasing concerns over the risk of transmission of infectious pathogenic agents from the use of human and animal plasma-derived TFs in both cell culture and drug delivery applications [13–15], rhTF has long been pursued in a variety of expression systems [16–24]. However, expression of fully functional TF has been proven to be challenging largely due to hTF’s complicated structural characteristics including 19 disulfide bonds and two homologous lobes (N-lobe and C-lobe). We have achieved a high level of expression yield of rhTF in rice (Oryza sativa L.). Expression yield is 40% of total soluble protein or 1% seed dry weight (10 g/kg) . The rice-derived rhTF is shown to be biochemically and structurally similar to hTF and mammalian cell-derived rhTF, and able to bind Fe3+ tightly yet reversibly . In the present work, we have characterized rice-derived rhTF’s TFR-binding, TFR-mediated endocytosis and intracellular processing, and its cellular iron delivery to diverse mammalian cells through various cell-based assays.
Comparison of TFR-binding affinity of rhTF and hTF
TFR binding parameters of TF proteins in HeLa cells
TFR binding parameters
Bmax (pmol/mg cell protein)1
6.78 ± 0.21
5.62 ± 0.20
4.42 ± 0.58
2.61 ± 0.46
TFR-mediated endocytosis of rhTF
Comparison of rhTF endocytosis in Caco-2 and HeLa cells
Pulse-chase assay of rhTF in Caco-2 and HeLa cells
Cellular iron delivery ability of rhTF to support cell proliferation and antibody production in mammalian cells
Iron is absolutely required to sustain mammalian cell growth and proliferation and is essential for such processes as electron transfer, oxygen transport, and DNA synthesis [30, 31]. We used two diverse cell lines (HL-60 and Sp2/0 hybridoma) to determine whether rhTF has similar biological activity as serum hTF to support cell growth and function. Furthermore, we measured the production of antibody from hybridoma cells as an indication of normal cellular function.
We then performed a dose response study to compare the activity of the hTF and rhTF using three cell culture performance metrics: 1.) log –phase cell proliferation after 3 days of culture, 2.) sustained cell growth as measured by cumulative cell density through 6 days of culture, and 3.) antibody productivity at the end-of-batch culture on day 6.
Furthermore, we compared rhTF to hTF using the parameter of 6-day cumulative cell density (CCD), also known as IVC-integral of the viable cell concentration. CCD is an important cell culture performance metric that measures the ability of a cell culture medium to support sustained high density cell growth  throughout an entire batch process. As shown in Figure 8B, rhTF and hTF have the similar CCD values at their equivalent concentrations. However, the generation of CCD was independent of the iron saturation status of both rhTF and hTF.
The concentration of monoclonal antibody produced by Sp2/0 cells grown in medium supplemented with a range of concentrations of rhTF or hTF at different degrees of iron saturation was compared (Figure 8C). rhTF and hTF stimulated the production of a similar amount of antibody at their equivalent concentration, and the production of antibody increased to the same extent with the increment dose for all of the transferrins tested. These results suggest that rhTF is equivalent to hTF for the delivery iron to hybridoma cells as evidenced by enhanced cell proliferation and the support of the cell’s physiological function of antibody production.
The essential function of TF is to transport and deliver irons to cells through the unique TF-TFR complex-mediated endocytosis pathway [1, 3]. Our previous cell-free biochemical and biophysical studies show that both lobes of rhTF bind Fe3+ tightly yet reversibly similarly to hTF [15, 25]. In this study we further characterize the TFR binding, TFR-mediated endocytosis and iron delivery function of rhTF using cell-based assays.
Our data show that the TFR-mediated endocytosis and intracellular processing of rhTF, as evaluated by total cell uptake, kinetics, and pulse-chase assays, is similar to that of hTF. This result is consistent with our previous finding in a competitive immunoassay that rhTF is equivalent to baby hamster kidney (BHK) cell derived recombinant N-His hTF in its ability to bind to the soluble portion of the TFR . It is also in good agreement with other reports that hTF’s internalization increases linearly with time in enterocyte-like Caco-2 cells due to this type of cells’ unique accumulation of TF . These results indicate that rhTF is similar to hTF in its ability of binding to human TFR, and then being endocytosed through TFR-mediated pathway. While the in vitro cell-based assays demonstrate the similarity of cellular iron delivery processing of rhTF and hTF, we have carried out a preliminary in vivo study to compare the serum half-life of rice-derived rhTF with that of hTF and the yeast-derived aglycosylated rhTF (CellPrimeTM rTransferrin AF, Millipore). The elimination half-lives (i.e. β-phase) of rice-derived rhTF, yeast-derived aglycosylated rhTF and hTF are 14.8, 13.8, and 18.6 hr, respectively (Unpublished data). The relatively shorter serum half-life could be due to the lack of N-linked glycans in the two recombinant transferrins [14, 15, 25]. Nevertheless, rice-derived rhTF is shown to have a sufficiently long serum half-life compared to native hTF. These results support that rhTF can be used as an animal-free alternative to serum hTF for pharmaceutical applications as a carrier to a number of drug molecules for drug targeting and delivery [6–8, 37].
We also use cell culture assay to assess the functional equivalency of rhTF to hTF. We demonstrate that rice-derived rhTF is equivalent to hTF to carry out cellular iron delivery for supporting cell growth and differentiation of HL-60 cells, which have been described as dependent on TF to support cell proliferation . Similarly, we show that rhTF and hTF has the same ability to deliver iron to support the cell growth and antibody production of Sp2/0 hybridoma cells, which are widely used for production of therapeutic antibodies . In addition, a study by D-Finitive Cell Technologies also indicates rhTF has equal activity to hTF and iron chelate to improve the expansion of both mononuclear cells and CD34+ stem cells (Paul Price, unpublished data). All these results demonstrate that rhTF is same as hTF to be able to deliver irons to various mammalian cells for supporting cell physiological function.
Our data show that the iron saturation status of rhTF or hTF has little impact on the stimulation of cell proliferation and antibody production in the HL-60 and murine hybridoma cells. Although apo-TF has no bound iron to deliver to cells and has low affinity for TFR , its equivalent stimulation effect on cell proliferation and antibody production as holo-TF is most likely due to the availability of iron in culture medium and the binding of iron by apo-TF. Iron is an ingredient in many classical formulations including MEM, DMEM, alpha MEM, M199, and DMEM/F12, and thus apo-TF is likely becoming saturated with iron from the medium.
Rice-derived rhTF is shown to be similar to hTF in its TFR binding, TFR-mediated endocytosis and cellular iron delivery function. This functional similarity, together with our previous reports showing the structural and biochemical similarities, makes rice-derived rhTF a low-cost and animal-free alternative to plasma-derived hTF for bioprocessing and biopharmaceutical applications. Currently, cell culture grade rhTF (OptiferrinTM) is available for use in cell culture applications. A more highly purified biopharmaceutical grade of rhTF is also being developed at Ventria Bioscience for use in pharmaceutical applications such as being used as a potential conjugate carrier to a number of drug molecules, including various chemotherapy drugs for drug targeting and delivery.
Recombinant hTF was expressed and purified from transgenic rice grains as described previously . The native hTF, ferric ammonium citrate, bovine serum albumin (BSA), 4′-hydroxyazobenzene-2-carboxylic acid (HABA)/Avidin reagent, and horseradish peroxidase (HRP)-conjugated anti-goat IgG antibody, sodium selenite, and ethanolamine were obtained from Sigma (St. Louis, MO). Cell culture Dulbecco’s modified Eagle’s medium (DMEM) and Fetal bovine serum (FBS) were products of Mediatech (Manassas, VA). Dulbecco’s modified Eagle’s medium-Ham F-12 nutrient mixture (DMEM/F12) was purchased from Life Technologies. Trypsin-EDTA was purchased from Gibco BRL (Rockville, MD). The Na-125I was from Perkin Elmer (Waltham, MA). The BCA (bicinchoninic acid) protein assay kit, Sulfo-NHS-LC-Biotin, and PBS reagents (NaCl, KCl, Na2HPO4, KH2PO4) was from Thermo-Fisher (Waltham, MA). The culture dishes were products of Corning (Corning, NY). Avidin-coated plates were products of Roche. TMB (3,3′,5,5′-Tetramethylbenzidine) Microwell Peroxidase Substrate System was the product of KPL (Gaithersburg, MD). Cellastim™ rhAlbumin is a product of InVitria (Fort Collins, CO). All other chemicals that are not specified above were purchased from Sigma.
HeLa human cervic carcinoma cells (CCL-2), Caco-2 human colon carcinoma cells (HTB-37), HL-60 human promyelocytic leukemia cells (CCL-240) and murinehybridoma cells, derived from a Sp2/0-Ag14 myeloma fusion partner (HB-72) were obtained from American Type Culture Collection (Rockville, MD, USA). All cell lines were maintained in DMEM/F12 medium supplemented with 10% FBS. Prior to assay, cells were washed three times with serum-free DMEM/F12 medium without TF.
Preparation of radiolabeled hTF and rhTF
Prior to radiolabeling, both rhTF and hTF were first saturated with iron by incubating 10 mg protein with 10 mg ferric ammonium citrate at 37°C in 2 mL of PBS, pH 7.2, for 2 hr followed by dialyzing against 2 L of PBS overnight at 4°C. Then, the iron-saturated TF was iodinated using the chloramines-T method . The specific activities of 125I-TF ranged from 400 to 900 cpm/ng.
TFR-binding affinity of rhTF
The TFR-binding affinity of rhTF was assessed using Caco-2 and HeLa cells. The Caco-2 and HeLa cells were adapted to growth as reported by Grasset et al.  and Zaro et al. , respectively, and then were seeded in a 12-well cluster plate to obtain confluent cell monolayers within a week after passage. Prior to TFR binding assay, Caco-2 and HeLa cells were washed twice with serum-free medium at room temperature and then pre-incubated with serum-free medium with 1 mg/ ml BSA at 37°C for 1 hr to deplete endogenous TF.
TFR-competition binding affinity assay in Caco-2 cells
One μg/ml 125I-hTF was mixed with 0.1, 0.3, 1, 3, 10 or 30 μg/ml unlabeled hTF or rhTF, respectively, and added to confluent Caco-2 cells followed by incubation at 4°C for 2 hr. The medium was then aspirated, and the cells were washed with ice-cold PBS and then solublized in 1 M NaOH. The amount of 125I-hTF and the cell protein content in the lysates were measured using a gamma counter and the BCA assay kit (Pierce), respectively. The non-specific surface binding of 125I-hTF was determined in wells containing cells supplemented with a 100-fold excess of unlabeled hTF or rhTF. The amount of 125I-hTF bound to TFR was calculated by subtracting non-specific surface bound 125I-hTF from the total amount of 125I-hTF in the lysates.
TFR-binding affinity assay in HeLa cells
Saturation radio-ligand binding assays were performed in HeLa cells to determine the binding capacity (Bmax) and equilibrium dissociation constant (Kd) values of rhTF. Increasing concentrations of 125I-hTF or rhTF (0.1, 0.3, 1, 3, or 10 μg/ml) were added to the confluent HeLa cells followed by incubation at 4°C for 2 hr. In parallel, cells incubated with a 100-fold excess of unlabeled hTF or rhTF was used to normalize the background caused by non-specific binding. Then, the TFR-binding affinity was assessed by the same method as described above in section TFR-competition binding affinity assay in Caco-2 cells.
TFR-mediated endocytosis of rhTF
The TFR-mediated endocytosis of rhTF was assessed using Caco-2 and HeLa cells, and the culture of these two cells was the same as described above in TFR binding affinity assay.
Comparison of endocytosis of rhTF in HeLa and Caco-2 cells
One μg/ml 125I-rhTF was added to confluent HeLa or Caco-2 cells followed by incubation at 37°C for 0.5, 1, 2, or 4 hr. In parallel, a 100-fold excess of unlabeled hTF was added to the wells containing 125I-rhTF to assay the non-specific binding of the 125I-rhTF. The medium was aspirated, and the cells were washed with ice-cold PBS and solublized in 1 M NaOH. The radioactivity of the lysates was counted using a gamma counter, and the cell protein content was determined using the BCA assay to determine the total cellular uptake of 125I-rhTF. TFR-mediated cellular uptake of rhTF was calculated by subtracting non-specific surface binding of rhTF from the total cellular uptake of rhTF.
Comparison of endocytosis of rhTF and hTF in Caco-2 cells
To investigate if the cellular uptake of rhTF is same as its native counterpart hTF, 1 μg/ml 125I-rhTF or hTF was added to confluent Caco-2 cells followed by incubation at 37°C for 0.5, 1, 2, or 4 hr. Then, the internalized 125I-rhTF or hTF in Caco-2 cells was assayed with the same method as described above for comparison of endocytosis of rhTF in HeLa and Caco-2 cells.
Pulse-chase assays of rhTF in HeLa and Caco-2 cells
Confluent HeLa and Caco-2 cells were first incubated with pulse medium containing 3 μg/ml 125I-rhTF at 37°C for 1 hr. In parallel, non-specific binding of 125I-rhTF was determined in wells containing 125I-rhTF and a 100-fold excess of unlabeled hTF. The unbound 125I-rhTF was then removed by three washes with serum-free medium. The pulse medium was aspirated, and the cell monolayers were washed with cold DMEM medium supplemented with 0.1% BSA to remove residual pulse medium. Chase medium, which contains 0.3 mg/ml unlabeled hTF to prevent re-internalization of 125I-rhTF, was then added to cells followed by incubation at 37°C for 1 or 3 hr. To determine the percentage of intact recycled 125I-rhTF in the chase medium, the collected medium was treated with 15% trichloroacetic acid for 15 min at 4°C. The medium samples were centrifuged, and the radioactivity in the pellet (intact) and supernatant (degraded) was determined. Meanwhile, the cell monolayers were incubated with trypsin, which detaches the cells and removes surface bound TF, and centrifuged to separate the surface bound (supernatant) and intracellular (pellet) 125I-rhTF. The data were presented as a percentage of initially endocytosed ligands (sum of release, surface-bound, and intracellular retention).
Pulse-chase assays of rhTF and hTF in Caco-2 cells
Confluent Caco-2 cells were first incubated with pulse medium containing 3 μg/ml 125I-hTF or rhTF at 37°C for 1 hr. Then, the endocytosis processing of radiolabeled rhTF and hTF in Caco-2 cells were assayed with the same method as described above in pulse-chase assays of rhTF in HeLa and Caco-2 cells.
The cellular iron delivery ability of rhTF to support cell growth and antibody production in mammalian cells
Cell proliferation assay using human promyelocytic leukemia HL-60 cells was performed in DMEM/F12 medium supplemented with recombinant human insulin as described , and with either hTF or rhTF at 0.005, 0.05, 0.5, 5, or 50 mg/L. Cells were washed in DMEM/F12 medium and seeded at 5,000 viable cells per well in a 96 well plate with triplicate wells per condition. Following a 3 day incubation, the relative viable cell count was determined by Resazurin (alamarBlue®) fluorescence assay  and reported as fluorescence units (FU)
Cell growth and antibody production of Sp2/0 hybridoma cells were assessed in a serum-free medium composed of DMEM/F12 medium supplemented with 10 mg/L recombinant human insulin, 0.0067 mg/L sodium selenite, 2 mg/L ethanolamine, 1 g/L Cellastim™ rhAlbumin from InVitria (Fort Collins, CO). A series of increasing concentrations of rhTF or hTF at 0.1, 0.3, 1, 3, 10, or 30 mg/L were used for the comparison of rhTF to hTF. Washed hybridoma cells were seeded in a 6 well plate at 0.5 x 105 viable cells/ml in triplicate 4 ml cultures. Cells were maintained in a humidified incubator at 37°C with 6% CO2. The concentration of viable cells was determined daily for 6 days by flow cytometer (Guava, Millipore) until end of batch culture was obtained (cell viability of 50% or less). The concentration of IgG1 monoclonal antibody secreted into the medium after 6 days of culture was determined by a fluorescence-based ELISA developed by InVitria using phycoerythrin conjugated detector antibody (Jackson ImmunoResearch, W. Grove, PA).
Human serum transferrin
Recombinant human serum transferrin
This work was supported in part by grants from NIH, R44 GM086916 (DZ) and R01 GM063647 (WCS).
- Baker HM, Anderson BF, Baker EN: Dealing with iron: common structural principles in proteins that transport iron and heme. Proc Natl Acad Sci USA. 2003, 100: 3579-3583. 10.1073/pnas.0637295100.View Article
- Cheng Y, Zak O, Aisen P, Harrison SC, Walz T: Structure of the human transferrin receptor–transferrin complex. Cell. 2004, 116: 565-576. 10.1016/S0092-8674(04)00130-8.View Article
- He QY, Mason A: Molecular aspects of release of iron from transferrin. Molecular and Cellular Iron Transport, CRC. Edited by: Templeton DM. 2002, 95-124.
- Laskey J, Webb I, Schulma HM, Ponka P: Evidence that transferrin supports cell proliferation by supplying iron for DNA synthesis. Exp Cell Res. 1988, 176: 87-95. 10.1016/0014-4827(88)90123-1.View Article
- Mortellaro S, Devine M: Advance in animal-free manufacturing of biopharmaceuticals. Biopharm Int. 2007, 20 (Supp): 30-37.
- Brandsma ME, Jevnikar AM, Ma S: Recombinant human transferrin: beyond iron binding and transport. Biotechnol Adv. 2011, 29: 230-238. 10.1016/j.biotechadv.2010.11.007.View Article
- Li H, Qian ZM: Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev. 2002, 22: 225-250. 10.1002/med.10008.View Article
- Qian ZM, Li H, Sun H, Ho K: Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev. 2002, 54: 561-587. 10.1124/pr.54.4.561.View Article
- Soni V, Jain SK, Kohli DV: Potential of transferrin and transferrin conjugates of liposomes in drug delivery and targeting. Am J Drug Deliv. 2005, 3: 155-170. 10.2165/00137696-200503030-00002.View Article
- Bai Y, Ann DK, Shen WC: Recombinant granulocyte colony-stimulating factor-transferrin fusion protein as an oral myelopoietic agent. Proc Natl Acad Sci USA. 2005, 102: 7292-7296. 10.1073/pnas.0500062102.View Article
- Widera A, Norouziyan F, Shen WC: Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery. Adv Drug Deliv Rev. 2003, 55: 1439-1466. 10.1016/j.addr.2003.07.004.View Article
- Banerjee D, Flanagan PR, Cluett J, Valberg LS: Transferrin receptors in the human gastrointestinal-tract - relationship to body iron stores. Gastroenterol. 1986, 91: 861-869.
- Grillberger L, Kreil TR, Nasr S, Reiter M: Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J. 2009, 4: 186-201. 10.1002/biot.200800241.View Article
- Keenan J, Pearson D, O’Driscoll L, Gammell P, Clynes M: Evaluation of recombinant human transferrin (DeltaFerrin(TM)) as an iron chelator in serum-free media for mammalian cell culture. Cytotechnology. 2006, 51: 29-37. 10.1007/s10616-006-9011-x.View Article
- Steere AN, Bobstb CE, Zhang D, Pettitd S, Kaltashovb IA, Huang N, Mason AB: Biochemical and structural characterization of recombinant Human Serum transferrin from rice (Oryza sativa L.). J Inorganic Biochemistry. 2012, 10.1016/j.jinorgbio.2012.07.005.
- Brandsma ME, Diao H, Wang X, Kohalmi SE, Jevnikar AM, Ma S: Plant-derived recombinant human serum transferrin demonstrates multiple functions. Plant Biotechnol J. 2010, 8: 489-505. 10.1111/j.1467-7652.2010.00499.x.View Article
- de Smit MH, Hoefkens P, de Jong G, van Duin J, van Knippenberg PH, van Eijk HG: Optimized bacterial production of nonglycosylated human transferrin and its half-molecules. Int J Biochem Cell Biol. 1995, 8: 839-850.View Article
- Finnis CJ, Payne T, Hay J, Dodsworth N, Wilkinson D, Morton P, Saxton MJ, Tooth DJ, Evans RW, Goldenberg H, Scheiber-Mojdehkar B, Ternes N, Sleep D: High-level production of animal-free recombinant transferrin from Saccharomyces cerevisiae. Microb Cell Fact. 2010, 9: 87-10.1186/1475-2859-9-87.View Article
- Funk WD, MacGillivray RT, Mason AB, Brown SA, Woodworth RC: Expression of the amino-terminal half-molecule of human serum transferrin in cultured cells and characterization of the recombinant protein. Biochemistry. 1990, 29: 1654-60. 10.1021/bi00458a043.View Article
- Mason AB, Funk WD, MacGillivray RT, Woodworth RC: Efficient production and isolation of recombinant amino-terminal half-molecule of human serum transferrin from baby hamster kidney cells. Protein Expr Purif. 1991, 2: 214-222. 10.1016/1046-5928(91)90074-S.View Article
- Mason AB, Miller MK, Funk WD, Banfield DK, Savage KJ, Oliver RW, Green BN, MacGillivray RT, Woodworth RC: Expression of glycosylated and nonglycosylated human transferrin in mammalian cells. Characterization of the recombinant proteins with comparison to three commercially available transferrins. Biochemistry. 1993, 32: 5472-5479. 10.1021/bi00071a025.View Article
- Mason AB, Halbrooks PJ, Larouche JR, Briggs SK, Moffett ML, Ramsey JE, Connolly SA, Smith VC, MacGillivray RT: Expression, purification, and characterization of authentic monoferric and apo-human serum transferrins. Protein Expr Purif. 2004, 36: 318-326. 10.1016/j.pep.2004.04.013.View Article
- Mizutani K, Hashimoto K, Takahashi N, Hirose M, Aibara S, Mikami B: Structural and functional characterization of recombinant human serum transferrin secreted from Pichia pastoris. Biosci Biotechnol Biochem. 2010, 74: 309-315. 10.1271/bbb.90635.View Article
- Steinlein LM, Ikeda RA: Production of N-terminal and C-terminal human serum transferrin in Escherichia coli. Enzyme Microb Technol. 1993, 15: 193-199. 10.1016/0141-0229(93)90137-Q.View Article
- Zhang D, Nandi S, Bryan P, Pettit S, Nguyen D, Santos MA, Huang N: Expression, purification, and characterization of recombinant human transferrin from rice (Oryza sativa L.). Protein Expr Purif. 2010, 74: 69-79. 10.1016/j.pep.2010.04.019.View Article
- Feder JN, Penny DM, Irrinki A, Lee VK, Lebrón JA, Watson N, Tsuchihashi Z, Sigal E, Bjorkman PJ, Schatzman RC: The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA. 1998, 95: 1472-1477. 10.1073/pnas.95.4.1472.View Article
- Penhallow RC, Brownmason A, Woodworth RC: Comparative studies of the binding and growth-supportive ability of mammalian transferrins in human-cells. J Cell Physiol. 1986, 128: 251-260. 10.1002/jcp.1041280217.View Article
- Taketani S, Kohno H, Sawamura T, Tokunaga R: Hemopexin-dependent down-regulation of expression of the human transferrin receptor. J Biol Chem. 1990, 265: 13981-13985.
- Lim CJ, Norouziyan F, Shen WC: Accumulation of transferrin in Caco-2 cells: a possible mechanism of intestinal transferrin absorption. J Control Release. 2007, 122: 393-398. 10.1016/j.jconrel.2007.03.021.View Article
- Aisen P, Listowsky I: Iron transport and storage proteins. Annu Rev Biochem. 1980, 49: 357-393. 10.1146/annurev.bi.49.070180.002041.View Article
- Anderson GJ, Frazer DM, McLaren GD: Iron absorption and metabolism. Curr Opin Gastroenterol. 2009, 25: 129-135. 10.1097/MOG.0b013e32831ef1f7.View Article
- Breitman TR, Collins SJ, Keene BR: Replacement of serum by insulin and transferrin supports growth and differentiation of the human promyelocytic cell line, HL-60. Exp Cell Res. 1980, 126: 494-498. 10.1016/0014-4827(80)90296-7.View Article
- Collins SJ: The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood. 1987, 70: 1233-1244.
- Gallagher R, Collins S, Trujillo J, McCredie K, Ahearn M, Tsai S, Metzgar R, Aulakh G, Ting R, Ruscetti F, Gallo R: Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood. 1979, 54: 713-733.
- Hauert AB, Martinelli S, Marone C, Niggli V: Differentiated HL-60 cells are a valid model system for the analysis of human neutrophil migration and chemotaxis. Int J Biochem Cell Biol. 2002, 34: 838-854. 10.1016/S1357-2725(02)00010-9.View Article
- Renard J, Spagnoli R, Mazier C, Sales M, Mandine E: Evidence that the monoclonal antibody production kinetics is related to the integral of the viable cells curve in batch systems. Biotechnol Lett. 1988, 10: 91-96. 10.1007/BF01024632.View Article
- Kim BJ, Zhou J, Martin B, Carlson OD, Maudsley S, Greig NH, Mattson MP, Ladenheim EE, Wustner J, Turner A, Sadeghi H, Egan JM: Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides. J Pharmacol Exp Ther. 2010, 334: 682-692. 10.1124/jpet.110.166470.View Article
- Chartrain M, Chu L: Development and Production of Commercial Therapeutic Monoclonal Antibodies in Mammalian Cell Expression Systems: An Overview of the Current Upstream Technologies. Curr Pharm Biotechnol. 2008, 9: 447-467. 10.2174/138920108786786367.View Article
- Sonoda S, Schlamowitz M: Studies of 125I trace labeling of immunoglobulin G by chloramines-T. Immunochemistry. 1970, 7: 885-898. 10.1016/0019-2791(70)90051-0.View Article
- Grasset E, Bernareu J, Pinto M: Epithelial properties of human colonic carcinoma cell line Caco-2 effect of secretagogues. Am J Physio. 1978, 173: 723-737.
- Zaro JL, Fei L, Shen WC: Recombinant peptide constructs for targeted cell penetrating peptide-mediated delivery. J Control Release. 2012, 158: 357-361. 10.1016/j.jconrel.2012.01.039.View Article
- Hamid R, Rotshteyn Y, Rabadi L, Parikh R, Bullock P: Comparison of alamar blue and MTT assays for high through-put screening. Toxicol In Vitro. 2004, 18: 703-10. 10.1016/j.tiv.2004.03.012.View Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.